TrovaGene Inc (NASDAQ:TROV)
TrovaGene Inc (NASDAQ:TROV) has announced entering into an agreement with AstraZeneca plc (ADR) (NYSE:AZN) that will see the latter supply Trovera® urine ctDNA biomarker tests and services. TrovaGene Inc is a precision medicine biotechnology company.
Initially, the Trovera® EGFR urine liquid biopsy test will be applied in an open label prospective biomarker trial to evaluate whether the collective use of noninvasive testing i.e. blood and urine testing are as effective and reliable as tissue testing in identifying the mutation status of the epidermal growth factor receptor (EGFR) T790M.
In a statement, TrovaGene Inc (NASDAQ:TROV) Chief Executive Officer, Bill Welch, said they are pleased to work AstraZeneca and to have their urine liquid biopsy test incorporated in a trial intended to explore new and non-invasive means of detecting the EGFR mutation.
TrovaGene Inc (NASDAQ:TROV) offers CLIA laboratory testing services for several clinical research third parties and biopharmaceutical companies. It is this expertise that has supported the development of biomarkers for PCM-075, a polo-like kinase 1 (PLK1) inhibitor. The company intends to use an acute myeloid leukemia (AML) genetic panel to evaluate the response to PCM-075 in its phase 1/2 trial.
Recently AstraZeneca got the US Food and Drug Administration for its Tagrisso (osimertinib) used in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer.
Additionally, AstraZeneca recently announced getting marketing approval from the Drug Controller General of India (DCGI) for asthma drug Symbicort. According to the company, Symbicort is a non-variable dose drug combination made of formoterol fumarate and budesonide dehydrate which are administered through a special device. The drug is meant for treatment of severe asthma as well as patients with severe chronic obstructive pulmonary disease (COPD) and who have a history of exacerbations.
Symbicort has been approved for use in asthma and COPD treatment in 910 countries. According to two major studies, the addition of budesonide to formoterol led to improvement in asthma symptoms and lung function in addition to reducing exacerbation.
Additionally, in two one-year clinical studies in patients suffering from COPD, Symbicort exhibited superior to placebo, formoterol, and budesonide in regards to lung function in addition to registering reduction in the rate of exacerbation as compared to formoterol and placebo.
TrovaGene Inc (NASDAQ:TROV) surged 37.36% and closed at $1.30 in Thursday’s trading session.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $TROV and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.